MeiraGTx Holdings PLC (MGTX)
| Market Cap | 767.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -80.11M |
| Shares Out | 44.45M |
| EPS (ttm) | -1.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140,439 |
| Open | 18.02 |
| Previous Close | 18.49 |
| Day's Range | 17.22 - 18.40 |
| 52-Week Range | 11.60 - 24.90 |
| Beta | 1.60 |
| Analysts | Strong Buy |
| Price Target | 36.57 (+111.7%) |
| Earnings Date | Nov 11, 2021 |
About MGTX
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentos...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MGTX stock is "Strong Buy." The 12-month stock price forecast is 36.57, which is an increase of 111.69% from the latest price.
News
MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation
LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast and con...
MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom
MeiraGTx Holdings plc (NASDAQ: MGTX) has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX). Xerostomia, or Dry mouth, happens ...
MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of ...
LONDON and NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive preliminary data from ...
MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regu...
LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call ...
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -13.46% and 38.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Reports Third Quarter 2021 Financial and Operational Results
LONDON and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third...
MeiraGTx to Participate in Upcoming Virtual Investor Conferences
LONDON and NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., P...
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q3 Earnings Expected to Decline
MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference
LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D.,...
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Trea...
LONDON and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced new data from subjects treated...
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 13.21% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Reports Second Quarter 2021 Financial and Operational Results
LONDON and NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the secon...
MeiraGTx Holdings PLC (MGTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Tops Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -25.58% and 83.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Announces Participation at Upcoming Investor Conferences
LONDON and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., p...
MeiraGTx (MGTX) Sees Hammer Chart Pattern: Time to Buy?
MeiraGTx Holdings (MGTX) has been struggling lately, but the selling pressure may be coming to an end soon
MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit
LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D.,...
MeiraGTx to Present at the 2021 Barclays Global Healthcare Conference
LONDON and NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D.,...
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to Decline
MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide
NEW YORK and BEIJING, Feb. 23, 2021 /PRNewswire/ -- Graviton Bioscience Corporation ("Graviton"), a privately held early-stage drug development company founded by Dr. Samuel Waksal, and Beijing Tide Pha...
MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia
Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET
MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., ...
MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., ...
Why MeiraGTx Holdings Stock Is Down Today
The company announced the pricing of a public offering of common stock.